FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Judith Wolf

Research Profile

Disorders

Procedures

Anatomy

Tumor Cells, Cultured

Physiology

Chemicals & Drugs

Concepts & Ideas

Living Beings

Nude Mouse

Genes & Molecular Sequences

Genes, p53

Co-author Network

Publications

TOP 3
Justin M Julius; Graciela M Nogueras-Gonzalez; Janos L Tanyi; Jack L Watkins; Judith K Wolf; Robert L Coleman; Judith A Smith
Evaluation of pegylated liposomal doxorubicin dose on the adverse drug event profile and outcomes in treatment of recurrent endometrial cancer.
Siqing Fu; David M Gershenson; Bryan T Hennessy; Adrienne Howard; Ed Jackson; Zhenlin Ju; John J Kavanagh; Vikas Kundra; Razelle Kurzrock; Charles F Levenback; Jane Li; Yang Li; Maurie Markman; Edward Atkinson; Robert C Bast; Robert L Coleman; Kevin R Coombes; Kristine Dice; Mary Dyer; Chaan S Ng; Anil K Sood; Katherine Stemke-Hale; Judith K Wolf; Gordon B Mills
Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.
Siqing Fu; Wei Hu; Revathy Iyer; John J Kavanagh; Robert L Coleman; Charles F Levenback; Anil K Sood; Judith K Wolf; David M Gershenson; Maurie Markman; Bryan T Hennessy; Razelle Kurzrock; Robert C Bast
Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Judith Wolf (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Justin M Julius; Graciela M Nogueras-Gonzalez; Janos L Tanyi; Jack L Watkins; Judith K Wolf; Robert L Coleman; Judith A Smith
Evaluation of pegylated liposomal doxorubicin dose on the adverse drug event profile and outcomes in treatment of recurrent endometrial cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2013;23(2):348-54.
2012: Siqing Fu; David M Gershenson; Bryan T Hennessy; Adrienne Howard; Ed Jackson; Zhenlin Ju; John J Kavanagh; Vikas Kundra; Razelle Kurzrock; Charles F Levenback; Jane Li; Yang Li; Maurie Markman; Edward Atkinson; Robert C Bast; Robert L Coleman; Kevin R Coombes; Kristine Dice; Mary Dyer; Chaan S Ng; Anil K Sood; Katherine Stemke-Hale; Judith K Wolf; Gordon B Mills
Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.
Gynecologic oncology 2012;126(1):47-53.
2011: Siqing Fu; Wei Hu; Revathy Iyer; John J Kavanagh; Robert L Coleman; Charles F Levenback; Anil K Sood; Judith K Wolf; David M Gershenson; Maurie Markman; Bryan T Hennessy; Razelle Kurzrock; Robert C Bast
Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer.
Cancer 2011;117(8):1661-9.
2010: Jubilee Brown; Judith A Smith; Lois M Ramondetta; Anil K Sood; Pedro T Ramirez; Robert L Coleman; Charles Levenback; Mark F Munsell; Maria Jung; Judith K Wolf
Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: results of a prospective phase 2 trial.
Cancer 2010;116(21):4973-9.
2010: Kwong-Kwok Wong; Yvonne T M Tsang; Michael T Deavers; Samuel C Mok; Zhifei Zu; Charlotte Sun; Anais Malpica; Judith K Wolf; Karen H Lu; David M Gershenson
BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.
The American journal of pathology 2010;177(4):1611-7.
2009: Celestine S Tung; Samuel C Mok; Yvonne T M Tsang; Zhifei Zu; Huijuan Song; Jinsong Liu; Michael T Deavers; Anais Malpica; Judith K Wolf; Karen H Lu; David M Gershenson; Kwong-Kwok Wong
PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2009;22(9):1243-50.
2009: Xiaoming Xie; Jennifer L Hsu; Min Gew Choi; Weiya Xia; Hirohito Yamaguchi; Chun-Te Chen; Bon Q Trinh; Zhen Lu; Naoto T Ueno; Judith K Wolf; Robert C Bast; Mien-Chie Hung
A novel hTERT promoter-driven E1A therapeutic for ovarian cancer.
Molecular cancer therapeutics 2009;8(8):2375-82.
2009: Kathleen M Schmeler; Saroj Vadhan-Raj; Pedro T Ramirez; Sachin M Apte; Lorenzo Cohen; Roland L Bassett; Revathy B Iyer; Judith K Wolf; Charles L Levenback; David M Gershenson; Ralph S Freedman
A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer.
Gynecologic oncology 2009;113(2):210-5.
2009: Anjali Gaikwad; Judith K Wolf; Jubilee Brown; Lois M Ramondetta; Judith A Smith
In vitro evaluation of the effects of gefitinib on the cytotoxic activity of selected anticancer agents in a panel of human endometrial cancer cell lines.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2009;15(1):35-44.
2009: Rodney J Hunter; Marisa A Navo; Premal H Thaker; Diane C Bodurka; Judith K Wolf; Judith A Smith
Dosing chemotherapy in obese patients: actual versus assigned body surface area (BSA).
Cancer treatment reviews 2009;35(1):69-78.
2008: Pedro T Ramirez; Kathleen M Schmeler; Judith K Wolf; Jubilee Brown; Pamela T Soliman
Robotic radical parametrectomy and pelvic lymphadenectomy in patients with invasive cervical cancer.
Gynecologic oncology 2008;111(1):18-21.
2008: Judith A Smith; Anjali Gaikwad; Jiang Yu; Judith K Wolf; Jubilee Brown; Lois M Ramondetta; Clinton F Stewart
In vitro evaluation of the effects of gefitinib on the modulation of cytotoxic activity of selected anticancer agents in a panel of human ovarian cancer cell lines.
Cancer chemotherapy and pharmacology 2008;62(1):51-8.
2007: Celestine S Tung; Pamela T Soliman; Michael J Wallace; Judith K Wolf; Diane C Bodurka
Successful catheter-directed venous thrombolysis in phlegmasia cerulea dolens.
Gynecologic oncology 2007;107(1):140-2.
2007: David R Crotzer; Charlotte C Sun; Robert L Coleman; Judith K Wolf; Charles Levenback; David M Gershenson
Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary.
Gynecologic oncology 2007;105(2):404-8.
2007: David R Crotzer; Judith K Wolf; Jacalyn B Gano; David M Gershenson; Charles Levenback
A pilot study of cisplatin, ifosfamide and mesna in the treatment of malignant mixed mesodermal tumors of the ovary.
Gynecologic oncology 2007;105(2):399-403.
2007: Jenifer M Saucier; Jiang Yu; Anjali Gaikwad; Robert L Coleman; Judith K Wolf; Judith A Smith
Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2007;13(1):39-45.
2006: Judith A Smith; Anjali Gaikwad; Lois M Ramondetta; Judith K Wolf; Jubilee Brown
Determination of the mechanism of gemcitabine modulation of cisplatin drug resistance in panel of human endometrial cancer cell lines.
Gynecologic oncology 2006;103(2):518-22.
2006: Judith K Wolf; Diane C Bodurka; Claire F Verschraegen; Charlotte C Sun; Donna Branham; Alfred D Jenkins; Neely Atkinson; David M Gershenson
A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer.
Gynecologic oncology 2006;102(3):468-74.
2006: Fernando C Maluf; Aliza L Leiser; Carol Aghajanian; Paul Sabbatini; Sandra Pezzulli; Dennis S Chi; Judith K Wolf; C Levenback; E Loh; David Spriggs
Phase II study of tirapazamine plus cisplatin in patients with advanced or recurrent cervical cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2006;16(3):1165-71.
2006: Michael Frumovitz; Robert L Coleman; Isis Gayed; Pedro T Ramirez; Judith K Wolf; David M Gershenson; Charles Levenback
Usefulness of preoperative lymphoscintigraphy in patients who undergo radical hysterectomy and pelvic lymphadenectomy for cervical cancer.
American journal of obstetrics and gynecology 2006;194(4):1186-93; discussion 1193-5.
2006: Robert L Coleman; Russell R Broaddus; Diane C Bodurka; Judith K Wolf; Thomas W Burke; John J Kavanagh; Charles Levenback; David M Gershenson
Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers.
Gynecologic oncology 2006;101(1):126-31.
2005: Judith A Smith; Hop Ngo; Miranda C Martin; Judith K Wolf
An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines.
Gynecologic oncology 2005;98(1):141-5.
2005: Anil K Sood; Robert L Coleman; Judith K Wolf; David M Gershenson
Selected highlights from the 5th International Conference on Ovarian Cancer. Houston, TX, USA, 1-4 December 2004.
Expert opinion on pharmacotherapy 2005;6(7):1269-75.
2005: Anil K Sood; Nadeem R Abu-Rustum; Richard R Barakat; Diane C Bodurka; Jubilee Brown; Michele L Donato; Elizabeth A Poynor; Judith K Wolf; David M Gershenson
Fifth International Conference on Ovarian Cancer: challenges and opportunities.
Gynecologic oncology 2005;97(3):916-23.
2005: Alfred D Jenkins; Lois M Ramondetta; Charlotte Sun; Taren Johnston; Judith K Wolf; Diane C Bodurka; Jubilee Brown; E Neely Atkinson; Charles Levenback
Phase II trial of capecitabine in recurrent squamous cell carcinoma of the cervix.
Gynecologic oncology 2005;97(3):840-4.
2005: Charlotte C Sun; Diane C Bodurka; Candice B Weaver; Rafia Rasu; Judith K Wolf; Michael W Bevers; Judith A Smith; J Taylor Wharton; Edward B Rubenstein
Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2005;13(4):219-27.
2004: Pedro T Ramirez; Michael Frumovitz; Judith K Wolf; Charles Levenback
Laparoscopic port-site metastases in patients with gynecological malignancies.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2004;14(6):1070-7.
2004: Judith K Wolf; Diane C Bodurka; Jacalyn B Gano; Michael Deavers; Lois M Ramondetta; Pedro T Ramirez; Charles Levenback; David M Gershenson
A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer.
Gynecologic oncology 2004;94(2):442-8.
2004: Michele L Donato; Ana Aleman; Richard E Champlin; Rima M Saliba; J Taylor Wharton; Thomas W Burke; Diane C Bodurka; Michael W Bevers; Charles Levenback; Judith K Wolf; Robert C Bast; Ralph S Freedman; Cindy Ippoliti; Molly Brewer; James L Gajewski; David M Gershenson
Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation.
Bone marrow transplantation 2004;33(12):1219-24.
2004: Veronica L Schimp; Cynthia Worley; Sandi Brunello; Charles C Levenback; Judith K Wolf; Charlotte C Sun; Diane C Bodurka; Pedro T Ramirez
Vacuum-assisted closure in the treatment of gynecologic oncology wound failures.
Gynecologic oncology 2004;92(2):586-91.
2004: Judith A Smith; Jubilee Brown; Miranda C Martin; Lois M Ramondetta; Judith K Wolf
An in vitro study of the inhibitory activity of gemcitabine and platinum agents in human endometrial carcinoma cell lines.
Gynecologic oncology 2004;92(1):314-9.
2003: Judith K Wolf; Eduardo L Franco; Jeffery M Arbeit; Kenneth R Shroyer; Tzyy-choou Wu; Carolyn D Runowicz; Guillermo Tortolero-Luna; Rolando Herrero; Christopher P Crum
Innovations in understanding the biology of cervical cancer.
Cancer 2003;98(9 Suppl):2064-9.
2003: Pedro T Ramirez; Judith K Wolf; Charles Levenback
Laparoscopic port-site metastases: etiology and prevention.
Gynecologic oncology 2003;91(1):179-89.
2003: Janos L Tanyi; Yutaka Hasegawa; Ruth Lapushin; Andrew J Morris; Judith K Wolf; Andrew Berchuck; Karen Lu; David I Smith; Kimberly R Kalli; Lynn C Hartmann; Karen McCune; David Fishman; Russell R Broaddus; Kwai Wa Cheng; E Neely Atkinson; Jose-Miguel Yamal; Robert C Bast; Edward Felix; Robert A Newman; Gordon B Mills
Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 1):3534-45.
2003: Mary E Gordinier; Anais Malpica; Thomas W Burke; Diane C Bodurka; Judith K Wolf; Anuja Jhingran; Pedro T Ramirez; Charles Levenback
Groin recurrence in patients with vulvar cancer with negative nodes on superficial inguinal lymphadenectomy.
Gynecologic oncology 2003;90(3):625-8.
2003: Lois M Ramondetta; Thomas W Burke; Anuja Jhingran; Rosemarie Schmandt; Michael W Bevers; Judith K Wolf; Charles Levenback; Russell R Broaddus
A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed müllerian tumors with evaluation of potential molecular targets.
Gynecologic oncology 2003;90(3):529-36.
2003: Hyun S Shvartsman; Karen H Lu; John Lee; Jim Lillie; Michael T Deavers; Stephanie Clifford; Judith K Wolf; Gordon B Mills; Robert C Bast; David M Gershenson; Rosemarie Schmandt
Overexpression of kallikrein 10 in epithelial ovarian carcinomas.
Gynecologic oncology 2003;90(1):44-50.
2003: Julie J Huh; Judith K Wolf; Diane L Fightmaster; Reuben Lotan; Michele Follen
Transduction of adenovirus-mediated wild-type p53 after radiotherapy in human cervical cancer cells.
Gynecologic oncology 2003;89(2):243-50.
2003: Janos L Tanyi; Andrew J Morris; Judith K Wolf; Xianjun Fang; Yutaka Hasegawa; Ruth Lapushin; Nelly Auersperg; Yury J Sigal; Robert A Newman; Edward Felix; E Neely Atkinson; Gordon B Mills
The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer.
Cancer research 2003;63(5):1073-82.
2003: Diane C Bodurka; Charles Levenback; Judith K Wolf; Jacalyn B Gano; J Taylor Wharton; John J Kavanagh; David M Gershenson
Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(2):291-7.
2003: Lois M Ramondetta; Diane C Bodurka; Guillermo Tortolero-Luna; Mary E Gordinier; Judith K Wolf; David M Gershenson; Anthony C Sciscione
Mentorship and productivity among gynecologic oncology fellows.
Journal of cancer education : the official journal of the American Association for Cancer Education 2003;18(1):15-9.
2002: Susan C Modesitt; Guillermo Tortolero-Luna; Jubilee B Robinson; David M Gershenson; Judith K Wolf
Ovarian and extraovarian endometriosis-associated cancer.
Obstetrics and gynecology 2002;100(4):788-95.
2002: Judith K Wolf; Alfred D Jenkins
Gene therapy for ovarian cancer (review).
International journal of oncology 2002;21(3):461-8.
2002: Pedro T Ramirez; Judith K Wolf; Anais Malpica; Michael T Deavers; Jinsong Liu; Russell R Broaddus
Wolffian duct tumors: case reports and review of the literature.
Gynecologic oncology 2002;86(2):225-30.
2002: Sean Tedjarati; Cheryl H Baker; Sachin Apte; Suyun Huang; Judith K Wolf; Jerald J Killion; Isaiah J Fidler
Synergistic therapy of human ovarian carcinoma implanted orthotopically in nude mice by optimal biological dose of pegylated interferon alpha combined with paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2413-22.
2002: John L Dalrymple; Charles Levenback; Judith K Wolf; Diane C Bodurka; Michael Garcia; David M Gershenson
Trends among gynecologic oncology inpatient deaths: is end-of-life care improving?
Gynecologic oncology 2002;85(2):356-61.
2002: Pedro T Ramirez; Susan C Modesitt; Mitchell Morris; Creighton L Edwards; Michael W Bevers; J Taylor Wharton; Judith K Wolf
Functional outcomes and complications of continent urinary diversions in patients with gynecologic malignancies.
Gynecologic oncology 2002;85(2):285-91.
2001: Pedro T Ramirez; David M Gershenson; Guillermo Tortolero-Luna; Lois M Ramondetta; Diane L Fightmaster; J Taylor Wharton; Judith K Wolf
Expression of cell-cycle mediators in ovarian cancer cells after transfection with p16(INK4a), p21(WAF1/Cip-1), and p53.
Gynecologic oncology 2001;83(3):543-8.
2001: Charles Levenback; Robert L Coleman; Thomas W Burke; DC Bodurka-Bevers; Judith K Wolf; David M Gershenson
Intraoperative lymphatic mapping and sentinel node identification with blue dye in patients with vulvar cancer.
Gynecologic oncology 2001;83(2):276-81.
2001: Jubilee B Robinson; D Singh; DC Bodurka-Bevers; J Taylor Wharton; David M Gershenson; Judith K Wolf
Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies.
Gynecologic oncology 2001;82(3):550-8.
2001: Michele L Donato; David M Gershenson; J Taylor Wharton; Cindy Ippoliti; Ana Aleman; DC Bodurka-Bevers; Michael W Bevers; Thomas W Burke; Charles Levenback; Judith K Wolf; Ralph S Freedman; Robert C Bast; James L Gajewski; Richard E Champlin
High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer.
Gynecologic oncology 2001;82(3):420-6.
2001: Gabriel N Hortobagyi; Naoto T Ueno; Weiya Xia; S Zhang; Judith K Wolf; Joe B Putnam; P L Weiden; Jie S Willey; M Carey; D L Branham; J Y Payne; SD Tucker; Chandra Bartholomeusz; RG Kilbourn; Robert L De Jager; Nour Sneige; Ruth Katz; Pervin Anklesaria; Nuhad K Ibrahim; James L Murray; Richard L Theriault; Vicente Valero; David M Gershenson; M W Bevers; Leaf Huang; Gabriel Lopez-Berestein; Mien-Chie Hung
Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(14):3422-33.
2001: Pedro T Ramirez; Charles Levenback; Thomas W Burke; Patricia J Eifel; Judith K Wolf; David M Gershenson
Sigmoid perforation following radiation therapy in patients with cervical cancer.
Gynecologic oncology 2001;82(1):150-5.
2001: Susan C Modesitt; P Ramirez; Z Zu; DC Bodurka-Bevers; David M Gershenson; Judith K Wolf
In vitro and in vivo adenovirus-mediated p53 and p16 tumor suppressor therapy in ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(6):1765-72.
2001: Adnan R Munkarah; Charles Levenback; Judith K Wolf; DC Bodurka-Bevers; Guillermo Tortolero-Luna; Robert Thomas Morris; David M Gershenson
Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer.
Gynecologic oncology 2001;81(2):237-41.
2001: Judith K Wolf; Pedro T Ramirez
The molecular biology of cervical cancer.
Cancer investigation 2001;19(6):621-9.
2001: Lynn P Parker; Pedro T Ramirez; Russell R Broaddus; S Sightler; Judith K Wolf
Low-grade ovarian cancer in an adolescent patient.
Gynecologic oncology 2001;80(1):104-6.
2000: Mary E Gordinier; Lois M Ramondetta; Lynn P Parker; Judith K Wolf; Michele Follen; David M Gershenson; DC Bodurka-Bevers
Survey of female gynecologic oncologists and fellows: balancing professional and personal life.
Gynecologic oncology 2000;79(2):309-14.
2000: Lynn P Parker; Judith K Wolf; Janet E Price
Adenoviral-mediated gene therapy with Ad5CMVp53 and Ad5CMVp21 in combination with standard therapies in human breast cancer cell lines.
Annals of clinical and laboratory science 2000;30(4):395-405.
2000: DC Bodurka-Bevers; Karen Basen-Engquist; CL Carmack; Mary A Fitzgerald; Judith K Wolf; Carl de Moor; David M Gershenson
Depression, anxiety, and quality of life in patients with epithelial ovarian cancer.
Gynecologic oncology 2000;78(3 Pt 1):302-8.
2000: Lois M Ramondetta; Gordon B Mills; Thomas W Burke; Judith K Wolf
Adenovirus-mediated expression of p53 or p21 in a papillary serous endometrial carcinoma cell line (SPEC-2) results in both growth inhibition and apoptotic cell death: potential application of gene therapy to endometrial cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(1):278-84.
1999: Judith K Wolf; Gordon B Mills; L Bazzet; Robert C Bast; Jack A Roth; David M Gershenson
Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status.
Gynecologic oncology 1999;75(2):261-6.
1999: Judith K Wolf; J Mullen; Patricia J Eifel; Thomas W Burke; Charles Levenback; David M Gershenson
Radiation treatment of advanced or recurrent granulosa cell tumor of the ovary.
Gynecologic oncology 1999;73(1):35-41.
1999: Judith K Wolf; T E Kim; Diane L Fightmaster; Diane C Bodurka; David M Gershenson; G Mills; J Taylor Wharton
Growth suppression of human ovarian cancer cell lines by the introduction of a p16 gene via a recombinant adenovirus.
Gynecologic oncology 1999;73(1):27-34.
1998: KR Brader; Judith K Wolf; S Chakrabarty; Janet E Price
Epidermal growth factor receptor (EGFR) antisense transfection reduces the expression of EGFR and suppresses the malignant phenotype of a human ovarian cancer cell line.
Oncology reports 1998;5(5):1269-74.
1998: David M Gershenson; Elvio G Silva; L Levy; Thomas W Burke; Judith K Wolf; Carmen Tornos
Ovarian serous borderline tumors with invasive peritoneal implants.
Cancer 1998;82(6):1096-103.
1998: Janet E Price; Judith K Wolf; Sen Pathak
Distinctive karyotypes and growth patterns in nude mice reveal cross-contamination in an established human cancer cell line.
Oncology reports 1998;5(1):261-6.
1997: KR Brader; Judith K Wolf; Mien-Chie Hung; Dihua Yu; Marta Crispens; Kenneth L van Golen; Janet E Price
Adenovirus E1A expression enhances the sensitivity of an ovarian cancer cell line to multiple cytotoxic agents through an apoptotic mechanism.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(11):2017-24.
1996: Charles Levenback; Mitchell Morris; Thomas W Burke; David M Gershenson; Judith K Wolf; J Taylor Wharton
Groin dissection practices among gynecologic oncologists treating early vulvar cancer.
Gynecologic oncology 1996;62(1):73-7.
1996: Judith K Wolf; Charles Levenback; Anais Malpica; Mitchell Morris; T Burke; MF Mitchell
Adenocarcinoma in situ of the cervix: significance of cone biopsy margins.
Obstetrics and gynecology 1996;88(1):82-6.
1993: Dihua Yu; Judith K Wolf; M Scanlon; Janet E Price; Mien-Chie Hung
Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.
Cancer research 1993;53(4):891-8.